header logo en

 

10 facts web

 

 

Atezolizumab in Combination With

Other Immune-modulating Therapies 

 
 
 
 Last updated: July 05, 2017
 STATUS: Recruiting (accepting new patients) (per ClinicalTrials.gov/NCT02174172)

WHO

is the trial for?

Patients with kidney cancer (Renal cell carcinoma, RCC) who currently meet the following criteria:

  • age 18 years or older
  • documented locally advanced or metastatic renal cell carcinoma
  • patients with or without prior atezolizumab treatment

WHAT

is the key question that this trial is attempting to answer?

This phase-I study aims to evaluate the safety and tolerability of a new immuno-therapy in combination with other immune-modulating therapies for kidney cancer.

It investigates the immune-checkpoint inhibitor atezolizumab (MPDL3280A) plus interferon alpha-2b in patients with inoperable, locally advanced, or metastatic renal cell carcinoma (RCC) or melanoma.

WHY

patients might want to participate?

This clinical trial offers patients an opportunity to access a new therapy that may be effective for kidney cancer. This trial will further support the research in kidney cancer and potentially help other patients with kidney cancer. The trial might or might not have benefit in your individual case. For more about the importance and benefits of joining clinical trials, please click here.

WHEN

will the trial be open?

The study is open (currently recruiting) – 200 patients worldwide are currently expected to participate.

WHERE

is the trial available?

The trial will be available in 8 cancer centres in 2 countries.
For a complete list of trial locations, please click here:
pdf List of study locations. (89 KB)
 

STUDY

DESIGN

What does the study look like?

There will be only one study arm (group) for RCC patients but two cohorts within this group: one with patients previously treated with MPDL3280A the other one with patients without prior treatment Which means all patients will receive the new treatment.

They will be assigned atezolizumab in combination with interferon alpha-2b.
  • atezolizumab is a fully human monoclonal antibody targeting PDL-1
  • interferon alpha-2b is an interferon
MPDL3280A interferon web

atezolizumab + interferon alpha-2b:
1) interferon alpha-2b is given subcutaneously every other day for up to 3 doses per week
2) atezolizumab is administered intravenously every three weeks

HOW

do I get more information?

Patient organisations supporting kidney cancer patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organisations serving kidney cancer patients. If there are no such organisations in your country, please email us for more information: This email address is being protected from spambots. You need JavaScript enabled to view it.

CONNECT

with other patients on this trial

If you want to connect with other patients considering or participating in this trial, you can find them here: List of organisations worldwide.

SHARE

your experience 

You want to share your experience on this trial?
Send us an e-mail to: This email address is being protected from spambots. You need JavaScript enabled to view it.
Note that your experience would be helpful for other patients and patient organisations.

RESULTS

of the study

No results are available at this time. Future results will be linked here.
Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.